Printer Friendly

HYAL ANNOUNCES ITS FIRST PHASE III CLINICAL TRIAL FOR INJECTABLE, INTRAVENOUS PAIN PRODUCT ALL LEAD PRODUCTS NOW IN PHASE III

 MISSISSAUGA, Ontario, March 17 /PRNewswire/ -- Hyal Pharmaceutical Corporation (NASDAQ-NMS: HYALF; TSE: HPC) announced today that the successful passage of its Investigational New Drug application (IND) through the Medical Products Agency (MPA) of Sweden, allows it to begin its first Phase III clinical trial on HYAL-AV2201 for the intravenous treatment of acute post-operative pain.
 The Phase III trial will be conducted at the Sahlgrenska Hospital in Gothenburg, Sweden and will compare the effectiveness and safety of Hyal's HA-Diclofenac formulation with a commercially available Diclofenac. Earlier studies have shown that a single-dose of HYAL-AV2201 provides profound pain relief of moderate to severe pain for up to 24 hours. The trial will involve up to 110 subjects and is expected to be completed within one year.
 HYAL-AV2201 is Hyal's third product to enter Phase III clinical evaluation during the past 10 months. HYAL-CT1101, for the topical treatment of basal cell carcinoma began multi-centre Phase III trials in September 1992 and HYAL-AT2101 for the topical treatment of superficial pain began Phase III evaluation in August, 1992, with the first of these studies being completed in December, 1992. All of Hyal's lead products are now in Phase III clinical trials.
 It is anticipated that HYAL-AV2201's approved Phase III trial application will form the basis for commencement of additional clinical trials to further evaluate its ability to treat chronic intractable pain, including cancer pain.
 Hyal Pharmaceutical Corporation specializes in the development and worldwide commercialization of pharmaceutical formulations utilizing its proprietary hyaluronic acid-based drug delivery technology. The company's efforts are concentrated in the treatment of pain, infection and skin cancer.
 -0- 3/17/93
 /CONTACT: Samuel S. Asculai, president & CEO, or David W. Harper, vice president-development of Hyal Pharmaceuticals, 416-366-4863; Diane Perry on the Financial Relations Board, 212-661-8030/
 (HYALF)


CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:

SM -- NY070 -- 7088 03/17/93 14:32 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1993
Words:310
Previous Article:NORTHWEST NATURAL GAS AND ISSC SIGN 5-YEAR TECHNOLOGY AGREEMENT
Next Article:SERVISTAR UNVEILS NEW CORPORATE DIRECTION
Topics:


Related Articles
HYAL PHARMACEUTICAL REPORTS HIGH EFFICACY LEVELS FROM FIRST PHASE III TRIAL
HYAL PHARMACEUTICAL PROVIDES DEVELOPMENT UPDATE AT SPROTT HEALTH CARE CONFERENCE
HYAL ANNOUNCES SECOND PHASE III CLINICAL TRIAL FOR TOPICAL PAIN PRODUCT
DRUGS TARGETED TO CANCER TUMORS BY HYAL'S DRUG DELIVERY TECHNOLOGY
POTENTIAL FOR HYAL PRODUCTS IN HEART DISEASE: PREVENTION OF RESTENOSIS TARGETED BY HYAL'S DRUG DELIVERY TECHNOLOGY
CLINICAL COMPARISON DEMONSTRATES HYANALGESE-D HAS THE EDGE OVER VOLTAREN EMULGEL IN RELIEVING ARTHRITIS PAIN
Mimetix Begins Nanox Clinical Trial
Cadence Pharmaceuticals Initiates Pivotal Phase III Clinical Trial Evaluating Intravenous Acetaminophen for Post-Operative Acute Pain.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters